Investigational Study of Delayed Release Metformin
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
In Phase 1 and 2 studies already conducted, Metformin DR, with its targeted delivery to the
distal small intestine, has shown the potential to be a safe and effective way to improve
glycemic control in patients with T2DM and CKD with less systemic metformin exposure. The
primary purpose of this Phase 3 clinical study is to collect pivotal data confirming the
safety and efficacy of Metformin DR in T2DM patients with varying renal function from normal
up to CKD3B.